Currently, out of the biological therapies, five original TNF inhibitors and already even more biosimilar TNF inhibitors, two interleukin-6 receptor (IL-6R) inhibitors, and one IL-1 receptor inhibitor as well as B-lymphocyte (CD20) and co-stimulatory signal (CD28-B7 interaction) for T-cell activation inhibitors are available for the treatment of RA (Table 1). This evidence concerns the gene TNF and rheumatoid arthritis.